Clinical Trials Using CD19CAR-CD3zeta-4-1BB-CD28-expressing Autologous T-Lymphocytes
Clinical trials are research studies that involve people. The clinical trials on this list are studying CD19CAR-CD3zeta-4-1BB-CD28-expressing Autologous T-Lymphocytes. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
CD19t T-APC, CAR T-cells, and Chemotherapy in Treating Patients with CD19 Positive Acute Lymphoblastic Leukemia
This pilot phase I trial studies the side effects of autologous T-cell antigen presenting cells expressing CD19t (CD19t T-antigen presenting cells [T-APCs]), CD19CAR-CD3zeta-4-1BB-CD28-expressing autologous T-lymphocytes (chimeric antigen receptor [CAR] T-cells), and chemotherapy in treating patients with CD19 positive acute lymphoblastic leukemia. CD19t T-antigen presenting cells are modified immune cells that may help stimulate CAR T-cells to persist for a longer period of time. CAR T-cells are modified T-cells that may be able to recognize a protein that may be found on leukemia cells, CD19, and kill them. Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CD19t T-antigen presenting cells, CAR T-cells, and chemotherapy may work better in treating patients with acute lymphoblastic leukemia.
Location: Seattle Children's Hospital, Seattle, Washington